Cotadutide Drug Asset Due Diligence Report 2026

This Cotadutide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Discontinued

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Cotadutide can convert its Synthetic peptide profile and GCGR x GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Cotadutide (query alias: cotadutide)
Modality / target	Synthetic peptide; GCGR x GLP-1R; GCGR agonists, GLP-1R agonists
Highest global status	Discontinued
Originator	MedImmune LLC
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05364931	Phase 2	Completed	54	Number of Participants With Adverse Events (AEs).
NCT05668936	Phase 1	Terminated	31	Time-matched change-from-baseline Fridericia's correction of QT interval (QTcF)
NCT05517226	Phase 1	Terminated	24	Maximum observed plasma (peak) drug concentration [Cmax]

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase II Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Cotadutide in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Phase 2; n=54; evaluation: not stated. Reported fields: Number of Participants With Adverse Events (AEs). = 13 Participants ; -; -

A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

Phase 2; n=248; evaluation: not stated. Reported fields: -; -; -

A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease

Phase 2; n=248; evaluation: Positive. Reported fields: UACR(14-week): Difference (%) = -43.9(95% CI, -54.7 to -30.6); Difference (%) = -49.9(95% CI, -59.3 to -38.4); UACR(14-week): Difference (%) = -43.9(95% CI, -54.7 to -30.6); Difference (%) = -49.9(95% CI, -59.3 to -38.4); UACR(14-week): Difference (%) = -43.9(95% CI, -54.7 to -30.6); Difference (%) = -49.9(95% CI, -59.3 to -38.4)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Cotadutide addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 31 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GCGR x GLP-1R records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-09-28	信达生物与健之佳达成战略合作，共筑零售减重新篇章	Approved	Financial terms not disclosed
2025-03-24	The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist	Phase 2	US$200.0M upfront; US$1,800.0M milestones
2025-03-17	American Regent entered into an agreement to commercialize Xeris Biopharma 's Gvoke VialDx ( glucagon ) for gastrointestinal use in the United States	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Composition comprising a GLP1r agonist and engineered extracellular vesicles comprising adiponectin, and uses thereof”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition comprising GLP-1 receptor agonist, GIP/GLP-1 receptor agonist and/or GLP-1/GIP/GCG receptor triple agonist”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION